m+Medelevator.RU
← Поиск публикаций
Journal of controlled release : official journal of the Controlled Release Society · 2025

Homotypic biomimetic nanotheranostics enhance locoregional Cherenkov radiation-induced photodynamic therapy and ferroptosis in early bone metastases.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Xue Rui, Li Shuai, Wang Fengyu, Zou Xiaojing, Zhang Beibei, Yu Chunshui, Chen Qiusong, Wu Jin, Sun Chunyang

Аннотация

Theranostics for deep-seated and multifocal bone metastases using conventional nanoparticulate strategies face significant challenges due to limited targeting and insufficient spatial controllability within the lesions. Here, we developed a sophisticated nanocarrier (MC@MH) camouflaged with the homologous prostate cancer cell membrane and ferritin-homing peptide (HKN22). Following systemic injection, the biomimetic nanotheranostics preferentially accumulated in bone metastases through a homotypic targeting mechanism. The acidic/H2O2-rich microenvironment triggered the degradation of MnO2 in MC@MH, leading to the release of Mn2+ ions that enhance magnetic resonance imaging (MRI) for bone metastases, particularly at early stages. The HKN22 further promoted interactions between MC@MH and intracellular ferritin. Guided by MRI, the separately administrated radionuclide (68Ga-PSMA-617) also actively navigated to metastatic tumors. Based on the Cherenkov radiation effect, it served as a light source in the lesions, precisely irradiating the photosensitizer (Chlorin e6) released from MC@MH. The cytotoxic ROS generated from Cherenkov radiation-induced PDT not only destroyed cancer cells but also destructed ferritin to initiate a cascade of ferroptosis. Overall, our strategy facilitated bone remodeling and repair while preserving bone homeostasis, offering a novel avenue for locoregional and precise theranostics against metastatic cancer in vivo.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты